3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Basal Cell
5
Medulloblastoma
4
Recurrence
3
Basal Cell Nevus Syndrome
2
Thrombocytosis
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Skin Neoplasms
1
Rhabdomyosarcoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hepatoblastoma
1
Hemorrhagic Disorders
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Glioma
1
Glioblastoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Bone Marrow Diseases
1
Blood Platelet Disorders
1
Blood Coagulation Disorders
1
Interventions
pembrolizumab
44
Paclitaxel
37
Carboplatin
30
Doxorubicin
11
Cisplatin
11
Bevacizumab
11
lenvatinib
9
Nivolumab
9
Docetaxel
9
Fulvestrant
8
Gemcitabine
7
Oxaliplatin
6
Fluorouracil
6
Pemetrexed
5
Letrozole
5
Ipilimumab
5
Cetuximab
5
spartalizumab
4
selinexor
4
dostarlimab
4
Trastuzumab
4
Irinotecan
4
trastuzumab deruxtecan
3
tisotumab vedotin
3
serabelisib
3
sacituzumab govitecan
3
ribociclib
3
olaparib
3
epacadostat
3
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Endometrial Neoplasms
×
sonidegib
×
Clear all
NCT02002689
2016-05-02
SIGNATURE
Novartis
Phase 2
Terminated
10 enrolled
9 charts